Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 positive, staying vigilant in looking for signs of adverse events (AEs) is ...

Patients on Enhertu lived for 13.2 months on average without their cancer progressing, while those on chemotherapy lived for 8.1 months. The most common side effects include low blood cell counts ...

At ASCO, commentators said the efficacy of the ADC would need to be balanced with its potential to cause side effects, as Enhertu can lead to more serious toxicities – such as interstitial lung ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

In the Japan business unit, sales of Lixiana, a direct oral anticoagulant; Tarlige analgesic; and ENHERTU ... and the absence of the impact of tax effect accounting in this fiscal year which ...

After medics confirmed the cancer had spread, they placed her on a new life-extending cancer drug called Enhertu ... Although she dreaded the side effects of chemo, she said she was "ready ...